NCT01127555

Salvage mFOLFOX in BTC After Failure of Gemcitabine

Phase II Study of Salvage mFOLFOX(5-fluorouracil, Leucovorin, Oxaliplatin) in Patients With Unresectable Biliary Tract Cancer (BTC) Who Had Failed Gemcitabine

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Chung-Ang University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of mFOLFOX (5-fluorouracil, leucovorin, oxaliplatin)as salvage therapy in patients with unresectable biliary tract cancer who had failed gemcitabine.

Conditions

• Unresectable Biliary Tract Cancer

Interventions

Type	Name	Description
DRUG	5-fluorouracil, leucovorin, oxaliplatin	D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks

Timeline

• Start date: 2010-04-01
• Primary completion: 2012-06-01
• Completion: 2013-01-01
• First posted: 2010-05-21
• Last updated: 2013-10-08

Locations

1 site across 1 country: South Korea